SA
Sign upLog In
CHGCY

Chugai Pharmaceutical Co., Ltd. is a leading biopharmaceutical company based in Japan, specializing in innovative drug development and manufacturing. The company's competitive position is bolstered by its strong pipeline of oncology and immunology products, particularly its collaboration with Roche, which enhances its market reach in both domestic and international markets.

HealthcareMedical - Pharmaceuticalshigh - Chugai benefits from economies of scale in production and R&D, allowing it to maintain high gross and operating margins despite significant investments in new drug development.

Business Overview

01Oncology drugs - 50%
02Immunology drugs - 30%
03Other pharmaceuticals - 20%

Chugai generates revenue primarily through the sale of patented pharmaceuticals, leveraging its strong R&D capabilities to develop innovative treatments. The company's collaboration with Roche provides access to advanced technologies and global distribution channels, enhancing its pricing power and market penetration.

What Moves the Stock

Approval of new drug applications, particularly in oncology and immunology

Sales growth from existing products, especially those in collaboration with Roche

Market expansion efforts in Asia and Europe

Changes in healthcare regulations impacting drug pricing

Watch on Earnings
Revenue growth rateOperating marginNet income margin

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption in drug development methodologies

Increased competition from generic drug manufacturers

Emerging biotech firms with innovative therapies

Low liquidity risk due to high current ratio (4.70)

Potential risks associated with R&D investments not yielding expected results

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - Chugai's performance is somewhat linked to GDP growth as healthcare spending typically increases in stronger economic conditions.

Interest Rates

Chugai's low debt levels (Debt/Equity of 0.01) minimize sensitivity to interest rate changes, but higher rates could impact overall healthcare spending.

Credit

minimal - The company has a strong balance sheet with low reliance on external financing.

Live Conditions
Dow Jones FuturesS&P 500 FuturesRussell 2000 Futures

Profile

growth - Investors are likely attracted to Chugai for its strong pipeline and potential for high revenue growth from innovative therapies.

moderate - The stock has shown some volatility, particularly in response to regulatory news and earnings announcements.

Key Metrics to Watch
Oncology drug sales growth
R&D expenditure as a percentage of revenue
Market share in key therapeutic areas
Regulatory approval timelines for new drugs

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.